Site Search

... passing the Senate Commerce and Labor Committee. SB0435 would expand coverage of biomarker testing for patients enrolled in  state employee health insurance plans and TennCare. American Cancer Society Cancer Action Network (ACS CAN) Tennessee Government Relations Director Maddie Michael attended Tuesday’s hearing to highlight the importance of this critical legislation in improving patient access to care. “Coverage for comprehensive biomarker testing will enable more patients to access the most effective treatments for their disease and can help achieve the triple aim of health care: better health outcomes, improved quality of life and reduced costs,” Michael said. Cancer patients who benefited from biomarker ...

... and partners are working together to make sure more Ohioans can benefit from this important testing.   What is Biomarker Testing? In cancer care, biomarkers are often used to help determine the best treatment for a patient . A “ biomarker ” is a sign of a normal biological process, ... are less likely to receive biomarker testing. Improving coverage for and access to biomarker testing across insurance types is key to reducing health disparities. Without action to expand coverage and access to biomarker testing, advances in precision medicine could increase existing disparities in health outcomes by race, ethnicity, income, and geography. Insurance coverage for biomarker testing is failing to keep pace with innovations and ...

... Presented by the American Cancer Society Cancer Action Network & Fred Hutch Cancer Center.  Cancer impacts all of us. Join us to hear from health leaders about how research funding drives cancer care and treatment. Learn about exciting research happening right now at Fred Hutch and how policy makers in Olympia and Washington DC can support breakthrough treatment and care that saves lives.  Spots are limited and open to all!  RSVP Today!   During the 2026 legislative session, the coalition regularly convened ...

... and S.809 to guarantee coverage of evidence-based biomarker testing, so that every patient has a fair shot at the most effective, personalized care. Video of jung_as_biomarker_story   What is Biomarker Testing? In cancer care, biomarkers are often used to help determine the best treatment ...   What are H. 4339 and S. 809, and why should Massachusetts pass them? H. 4339 and S. 809 would require MassHealth and state-regulated health insurance plans to cover biomarker testing when it is supported by strong clinical evidence and guidelines. As a global leader in life sciences and cancer research, Massachusetts has an opportunity to improve patient outcomes, advance health equity, and ensure that residents of the Commonwealth have access to the most effective, personalized medical care available. This is how we ...